Nasdaq stocks posting largest percentage decreases
AP - Wed Dec 24, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
TRVN: 5.38 (-0.37), SNFCA: 5.08 (-0.36)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 24, 11:44AM CST
TRVN: 5.38 (-0.37), EXXI: 3.45 (-0.22), NES: 4.96 (-0.44), ASPS: 33.81 (+4.37), CAMP: 17.74 (-1.98), ZAZA: 3.20 (+0.70), EXE: 1.55 (+0.25), VII: 1.83 (+0.38), NQ: 4.32 (-0.36), ARDX: 20.97 (-1.74), SRNE: 9.50 (+0.99), VRTB: 3.49 (-0.12), ANFI: 12.75 (+2.95), ATOS: 1.43 (+0.37), WATT: 9.46 (+1.49), COOL: 1.15 (+0.14), AMBR: 9.90 (-0.59), WRES: 1.66 (-0.13), SPP: 1.63 (+0.18), KONE: 2.81 (-0.38)
Trevena Appoints Anne M. Phillips to the Board of Directors
Business Wire - Wed Dec 17, 6:00AM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that Anne M. Phillips, M.D. has been appointed to Trevena's Board of Directors. Dr. Phillips replaces Farah Champsi, managing director at Alta Partners, who is stepping down from the Board following the Company's initial public offering earlier this year.
TRVN: 5.38 (-0.37)
Trevena (TRVN) in Focus: Stock Rallies 7.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 7:44AM CST
Trevena, Inc. (TRVN) was a big mover last session, as the company saw its shares surge over 7% on the day.
BIIB: 340.89 (+5.13), TRVN: 5.38 (-0.37), ILMN: 186.22 (+2.72), AFFX: 9.80 (+0.05)
InsiderInsights.com Daily Round Up 12/10/14: PSEC, TWI, SGEN, ATLS
InsiderInsights - at Seeking Alpha - Thu Dec 11, 12:18AM CST
TRVN: 5.38 (-0.37), HSGX: 10.51 (-0.46), VR: 41.51 (+0.19), LBTYK: 49.10 (+0.05), ATLS: 30.37 (-0.07), UHS: 111.87 (+0.99), CLH: 49.40 (-0.60), WMS: 23.00 (+0.28), ALEX: 40.09 (+0.38), CDW: 35.75 (+0.14), BABY: 36.45 (+1.14), PRSS: 2.42 (-0.01), SGEN: 31.10 (-0.14), CO: 4.40 (+0.05), HBI: 110.93 (-0.07), TWI: 10.92 (-0.20), HSIC: 137.87 (+0.15), PSEC: 8.59 (-0.02), XLRN: 38.80 (+0.80)
Trevena Announces Closing of Public Offering and Partial Exercise of Underwriters' Option to Purchase Additional Shares
Business Wire - Wed Dec 10, 3:01PM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the closing of its underwritten public offering of 11,250,000 shares of common stock at a price to the public of $4.00 per share. In addition, the Company announced today that it closed the sale of an additional 1,598,000 shares of common stock pursuant to the partial exercise of the option to purchase additional shares by the underwriters of the public offering. With this exercise, the Company has sold 12,848,000 shares in this offering, representing net proceeds of approximately $47.7 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Trevena.
TRVN: 5.38 (-0.37)
Anxiety Disorders Therapeutic Pipeline Market Review H2 2014 Report at RnRMarketReserach.com
PRWeb - Sun Dec 07, 6:31PM CST
The report "Anxiety Disorders Pipeline Review H2 2014" is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/anxiety-diso...eport.html .
TRVN: 5.38 (-0.37), JNJ: 104.59 (+0.31), LLY: 70.16 (+0.42), CNCE: 11.76 (+0.11), OMER: 22.09 (+0.48)
Nasdaq stocks posting largest volume increases
AP - Fri Dec 05, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
BIRT: 6.60 (+0.02), TRVN: 5.38 (-0.37), ISIG: 3.78 (+0.02), FIVE: 38.76 (-0.11), OPB: 27.68 (+0.03)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 8:10AM CST
ANV: 0.88 (+0.02), TRVN: 5.38 (-0.37), RADA: 2.74 (+0.16), GLP: 34.90 (-0.19), QTM: 1.80 (unch), AEO: 13.53 (+0.02), FUEL: 17.08 (-0.12), GOL: 5.16 (-0.04), ULTA: 128.18 (-0.38), FIVE: 38.76 (-0.11), BIG: 39.31 (+0.70), ALSK: 1.82 (-0.05)
Trevena prices offering
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 5:59AM CST
TRVN: 5.38 (-0.37)
Trevena Announces Pricing of Public Offering
Business Wire - Thu Dec 04, 6:00PM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the pricing of its underwritten public offering of 11,250,000 shares of common stock at a price to the public of $4.00 per share. The gross proceeds to Trevena from this offering are expected to be approximately $45,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trevena. In addition, Trevena has granted the underwriters a 30-day option to purchase up to 1,687,500 additional shares of common stock from Trevena at the public offering price. The offering is expected to close on December 10, 2014, subject to customary closing conditions.
TRVN: 5.38 (-0.37)
Trevena commences stock offering
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 7:56AM CST
TRVN: 5.38 (-0.37)
Trevena Announces Commencement of Public Offering
Business Wire - Mon Dec 01, 6:00AM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that it intends to offer and sell $40.0 million of shares of its common stock in an underwritten public offering. Barclays Capital Inc., Cowen and Company, LLC and Jefferies LLC are acting as joint book-running managers for the proposed offering. JMP Securities LLC and Needham & Company, LLC are acting as co-managers.
TRVN: 5.38 (-0.37)
Trevena reports positive top-line data from Phase 2 pain med trial
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 3:49PM CST
TRVN: 5.38 (-0.37)
Trevena Announces Positive Top-Line Results from Phase 2a/b Study of TRV130 in Acute Postoperative Pain
Business Wire - Mon Nov 17, 3:01PM CST
--- Demonstrated differentiation versus morphine -
TRVN: 5.38 (-0.37)
Trevena misses by $0.14
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:20AM CST
TRVN: 5.38 (-0.37)
Trevena Reports Third Quarter 2014 Financial Results and Provides a Corporate Update
Business Wire - Tue Nov 11, 6:00AM CST
--- TRV027 AHF Phase 2b trial enrollment progressing as planned -
TRVN: 5.38 (-0.37)